| Literature DB >> 27699241 |
Kamal El Bissati1, Aziz A Chentoufi2, Paulette A Krishack3, Ying Zhou1, Stuart Woods4, Jitender P Dubey5, Lo Vang6, Joseph Lykins1, Kate E Broderick7, Ernest Mui1, Yasuhiro Suzuki8, Qila Sa8, Stephanie Bi1, Nestor Cardona1, Shiv K Verma5, Laura Fraczek1, Catherine A Reardon3, John Sidney9, Jeff Alexander6, Alessandro Sette9, Tom Vedvick10, Chris Fox10, Jeffrey A Guderian10, Steven Reed10, Craig W Roberts4, Rima McLeod1.
Abstract
We created and tested multi-epitope DNA or protein vaccines with TLR4 ligand emulsion adjuvant (gluco glucopyranosyl lipid adjuvant in a stable emulsion [GLA-SE]) for their ability to protect against Toxoplasma gondii in HLA transgenic mice. Our constructs each included 5 of our best down-selected CD8+ T cell-eliciting epitopes, a universal CD4+ helper T lymphocyte epitope (PADRE), and a secretory signal, all arranged for optimal MHC-I presentation. Their capacity to elicit immune and protective responses was studied using immunization of HLA-A*11:01 transgenic mice. These multi-epitope vaccines increased memory CD8+ T cells that produced IFN-γ and protected mice against parasite burden when challenged with T. gondii. Endocytosis of emulsion-trapped protein and cross presentation of the antigens must account for the immunogenicity of our adjuvanted protein. Thus, our work creates an adjuvanted platform assembly of peptides resulting in cross presentation of CD8+ T cell-eliciting epitopes in a vaccine that prevents toxoplasmosis.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27699241 PMCID: PMC5033759 DOI: 10.1172/jci.insight.85955
Source DB: PubMed Journal: JCI Insight ISSN: 2379-3708